CNSP Stock Overview
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CNS Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$2.98 |
| 52 Week Low | US$0.19 |
| Beta | 1.09 |
| 1 Month Change | -45.60% |
| 3 Month Change | -51.39% |
| 1 Year Change | -88.14% |
| 3 Year Change | -99.67% |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
CNS Pharmaceuticals reports Q2 results
Aug 15Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation
Dec 04
CNS Pharmaceuticals sinks after pricing equity offering of $10M
Dec 23How Many CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Shares Did Insiders Buy, In The Last Year?
Dec 09Shareholder Returns
| CNSP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 1.0% |
| 1Y | -88.1% | 10.6% | 21.9% |
Return vs Industry: CNSP underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: CNSP underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CNSP volatility | |
|---|---|
| CNSP Average Weekly Movement | 17.3% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNSP's share price has been volatile over the past 3 months.
Volatility Over Time: CNSP's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | John Climaco | www.cnspharma.com |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals, Inc. Fundamentals Summary
| CNSP fundamental statistics | |
|---|---|
| Market cap | US$2.17m |
| Earnings (TTM) | -US$18.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs CNSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNSP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.85m |
| Earnings | -US$18.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -6.8% |
How did CNSP perform over the long term?
See historical performance and comparison